63435-16-5

Basic information

• Product Name: Methyl 4-amino-3-hydroxybenzoate
• Synonyms: 3-HYDROXY-4-AMINOBENZOIC ACID ETHYL ESTER;4-AMINO-3-HYDROXYBENZOIC ACID ETHYL ESTER;METHYL-3-HYDROXY-4-AMINOBENZOATE;METHYL 4-AMINO-3-HYDROXYBENZENECARBOXYLATE;METHYL 4-AMINO-3-HYDROXYBENZOATE;4-Amino-3-hydroxybenzoic acid methyl ester;3-HYDROXY-4-AMINOBENZOIC ACID ETHYL ESTER 97%;3-Hydroxy-4-aminobenzoic acid methyl ester
• CAS NO: 63435-16-5
• Molecular Formula: C₈H₉NO₃
• Molecular Weight: 167.16
• Product Categories: Aromatic Esters;Benzoic acid
• Mol File: 63435-16-5.mol
• Article Data: 28

Chemical Properties

• Melting Point: 120-122°C
• Boiling Point: 364.5 °C at 760 mmHg
• Flash Point: 174.2 °C
• Appearance: /
• Density: 1.305 g/cm³
• Vapor Pressure: 7.99E-06mmHg at 25°C
• Refractive Index: 1.605
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.94±0.10(Predicted)
• BRN: 608716
• CAS DataBase Reference: Methyl 4-amino-3-hydroxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-amino-3-hydroxybenzoate(63435-16-5)
• EPA Substance Registry System: Methyl 4-amino-3-hydroxybenzoate(63435-16-5)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 63435-16-5(Hazardous Substances Data)

Usage

Uses

Methyl 4-amino-3-hydroxybenzoate is used as an important raw material and intermediate used in Organic Synthesis, Pharmaceuticals, Agrochemicals and Dyestuff.

InChI:InChI=1/C8H9NO3/c1-12-8(11)5-2-3-6(9)7(10)4-5/h2-4,10H,9H2,1H3

Upstream product

• 2374-03-0 4-aminosalicylic acid 
• 75-36-5 acetyl chloride 
• 619-14-7 3-hydroxy-4-nitro-benzoic acid 
• 713-52-0 methyl 3-hydroxy-4-nitrobenzoate 
• 91-66-7 N,N-diethylaniline 
• 67-56-1 methanol 

Downstream Products

• 39267-53-3 methyl 4-acetamido-3-hydroxybenzoate 
• 142165-99-9 4-(2-chloro-acetylamino)-3-hydroxy-benzoic acid methyl ester 
• 72752-80-8 methyl 2-oxo-2,3-dihydro-1,3-benzoxazole-6-carboxylate 
• 876162-62-8 methyl 2-(hydroxy)formanilide-4-carboxylate 
• 90800-42-3 8-hydroxy-quinoline-6-carboxylic acid 
• 257292-10-7 methyl 4-amino-3-(4-heptyloxy)benzoate 
• 257292-09-4 methyl 4-amino-3-(3-pentyloxy)benzoate 
• 142166-00-5 methyl 3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carboxylate 
• 13065-48-0 4-[(N,N-diethyl-glycyl)-amino]-hydroxy-benzoic acid methyl ester 
• 895128-29-7 4-[2-(4-benzyloxy-3-methyl-phenyl)-2-ethyl-butyrylamino]-3-hydroxy-benzoic acid methyl ester 
• 179950-69-7 7-methoxycarbonyl-2-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine 
• 136663-23-5 methyl 2-methyl-1,3-benzoxazole-6-carboxylate 
• 737802-03-8 2-amino-5-(1-ethyl-1-hydroxy-propyl)-phenol 
• 695186-40-4 3-hydroxy-4-[(3-nitrobenzoyl)amino]benzoic acid methyl ester 

Relevant articles and documents

Photoconductive bent-core liquid crystalline radicals with a paramagnetic polar switchable phase

A series of self-organizing bent-core derivatives 1[12,n], containing a highly π-delocalized stable radical as the central angular structural element, is described. The planarity of the open-shell core permits efficient π-π stacking, which results in the formation of B2 and soft crystalline phases above 100 °C. Optical, XRD and dielectric analyses of 1[12,12] indicate that the ground state of the observed B2 phase is polar antiferroelectric of type SmCAPA exhibiting tristable electro-optical switching. SQUID and EPR measurements revealed strong antiferromagnetic spin-spin exchange interactions below the isotropic phase, which have been estimated at θ = -46 cm-1 with the Curie-Weiss law. Transient photoconductivity was observed in the B2 phase with a hole carrier mobility μh of 1.4 × 10-4 cm2 V-1 s-1

Design, synthesis and pharmacology of aortic-selective acyl-CoA: Cholesterol O-acyltransferase (ACAT/SOAT) inhibitors

We describe our molecular design of aortic-selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT, also abbreviated as SOAT) inhibitors, their structure–activity relationships (SARs) and their pharmacokinetic (PK) and pharmacological profiles. The connection of two weak ligands—N-(2,6-diisopropylphenyl)acetamide (50% inhibitory concentration [IC50] = 8.6 μM) and 2-(methylthio)benzo[d]oxazole (IC50 = 31 μM)—via a linker comprising a 6 methylene group chains yielded a highly potent molecule, 9-(benzo[d]oxazol-2-ylthio)-N-(2,6-diisopropylphenyl)nonanamide (3h) that exhibited high potency (IC50 = 0.004 μM) toward aortic ACAT. This head-to-tail design made it possible to markedly enhance the activity to 2150- to 7750-fold and to discriminate the isoform-selectivity based on the double-induced fit mechanism. At doses of 1 and 3 mg/kg, 3h significantly decreased the lipid-accumulation areas in the aortic arch to 74 and 69%, respectively without reducing the plasma total cholesterol level in high fat- and cholesterol-fed F1B hamsters. Here, we demonstrate the antiatherosclerotic effect of 3h in vivo via its direct action on aortic ACAT and its powerful modulator of cholesterol level. This molecule is a potential therapeutic agent for the treatment of diseases involving ACAT-1 overexpression.

COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a compound inhibiting CDK5-mediated PPARG phosphorylation and a pharmaceutical composition for treating PPARG-related diseases containing the same as an active ingredient. A compound represented by formula 1 or an optical